RSV Vaccination Experiences in Queensland Infants
Part of Infections clinical trials.
This study asks parents in Queensland about their infant's RSV (respiratory syncytial virus) vaccination status and experiences. RSV is a common virus that can cause serious breathing problems in babies, and this research helps understand vaccination patterns.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a parent of a baby born between February 1, 2024 and April 15, 2025
- You are at least 18 years old
- You live in Queensland, Australia
- You can read and understand the study information and consent form
- You agree to report any health concerns that might be related to the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two ways to protect babies from RSV: a vaccine given to pregnant women, and an antibody shot given to newborns. Both are already approved—this study checks if using them together works better than either alone.
This trial tests giving a medicine called nirsevimab to newborns and a possible vaccine to pregnant mothers to prevent RSV, a serious lung infection in babies. It checks if combining both is safe and works better than nirsevimab alone.
This study tests whether giving a special antibody medicine (called RSV-SMA) to babies aged 6–9 months can help prevent respiratory syncytial virus (RSV), a common virus that causes serious breathing problems in young children. Your baby would receive the medicine and be followed to see if it helps protect them.
This study looks at how well RSV vaccines or antibody shots protect babies from severe respiratory infections. If your baby is under 1 year old, lives in Connecticut, and gets sick with a respiratory infection, they may be able to join.
This study tests an approved RSV vaccine given to pregnant women. The goal is to see if it safely protects their babies from severe RSV lung infections during the first months of life.
This registry follows pregnant people who received an RSV vaccine during a specific window (32 to 36 weeks) to monitor safety. If you got the shot in that time, your information helps researchers understand how well the vaccine works in pregnancy.
Hear when a new RSV Immunization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.